renal-cell-carcinoma

Documents about renal-cell-carcinoma

• Granulocyte-macrophage Colony-stimulating Factor, Interferon and Interleukin-2 as Adjuvant Treatment for Renal Cancer#967717ClinicalTrials.gov
• Phase 1b/2 Study of Carfilzomib in Relapsed Solid Tumors, Multiple Myeloma, or Lymphoma#851901ClinicalTrials.gov
• FT516 in Combination With Monoclonal Antibodies in Advanced Solid Tumors#872147ClinicalTrials.gov
• Gemcitabine Hydrochloride, Cisplatin, and Sunitinib Malate as First-Line Therapy in Treating Patients With Locally Advanced And/or Metastatic Transitional Cell Carcinoma of the Urothelium (SUCCINCT)#1032085ClinicalTrials.gov
• Multi‐Omics and Machine Learning‐Uncovered FLT1‐Mediated Epithelial‐Endothelial Crosstalk in Cellular Senescence Driving Clear Cell Renal Cell Carcinoma Malignancy.#30584NCBI PubMed Central
• Integrated multi-omics analysis reveals folate metabolism-related genes as prognostic markers and therapeutic targets in clear cell renal cell carcinoma.#988579NCBI PubMed Central
• Study Comparing the Standard Administration of IO Versus the Same IO Administered Each 3 Months in Patients in Response After 6 Months of Standard IO#141014ClinicalTrials.gov
• Gemcitabine, Paclitaxel, and Cisplatin in Treating Patients With Advanced Cancer of the Urothelium#891871ClinicalTrials.gov
• Functionally Characterizing the Renal Cell Carcinoma Tumor-Immune Microenvironment via Patient-Derived Ex Vivo Models.#154432NCBI PubMed Central
• Tertiary lymphoid structures are reservoirs of stem-like tumor-specific T cells in renal cell carcinoma#215686Ora Oxford University Research
• An Exploratory Study on the Failure of Immunotherapy With Voronib Combined With Everolimus#332768ClinicalTrials.gov
• Utility of Tumor Sphericity on CT for Differentiating Fat-Poor Angiomyolipoma from Renal Cell Carcinoma.#438991NCBI PubMed Central
• A Prospective，Single Arm, Multicenter Clinical Study of BTLA Monoclonal Antibody JS004 (B/T Lymphocyte Attenuator Factor Monoclonal Antibody) in Combination With Toripalimab in Patients With Unresectable or Advanced Renal Cell Carcinoma Who Had Failed Previous Immunotherapy#876074ClinicalTrials.gov
• Role of PRoactivE Coaching on PAtient REported Outcome in Advanced or Metastatic RCC Treated With Sunitinib or a Combination of Pembrolizumab + Axitinib or Avelumab + Axitinib in First Line Therapy#429671ClinicalTrials.gov
• Aflac ST0901 CHOANOME - Sirolimus in Solid Tumors#838158ClinicalTrials.gov
• <i>CIS Predicts PFS in mccRCC</i>#264753Figshare
• A contrast-enhanced ultrasound-based nomogram for preoperative prediction of pseudocapsule status in localized clear cell renal cell carcinoma: a retrospective study.#362186NCBI PubMed Central
• A Pilot Study of Blood-based Biomarkers for Response to Immune Checkpoint Inhibitors#902710ClinicalTrials.gov
• The Immune Effects of Fermented Wheat Germ Nutritional Supplementation in Patients With Advanced Solid Tumor Cancers Being Treated With Standard of Care Checkpoint Inhibitors#373586ClinicalTrials.gov
• First-in-human Phase I Study to Evaluate Safety, Tolerability and Antineoplastic Activity of OATD-02 in Patients with Selected Advanced And/or Metastatic Solid Tumours#414504ClinicalTrials.gov
• Interleukin-2 With Sorafenib (BAY 43-9006) for Unresectable or Metastatic Clear Cell Renal Carcinoma (RCC) and Metastatic Melanoma#836524ClinicalTrials.gov
• Interventional Study of INCB 99280 With Ipilimumab in Participants With Select Solid Tumors#871114ClinicalTrials.gov
• 18F-T2 PET/CT Imaging for CAIX Positive Solid Tumors#881267ClinicalTrials.gov
• Clinical and Molecular Validation of the Very Favorable IMDC Risk Group in Metastatic Renal Cell Carcinoma.#25585NCBI PubMed Central
• Advancing early detection of chromophobe renal cell carcinoma: a Bayesian optimization approach to machine learning models.#242288NCBI PubMed Central
• Ziv-Aflibercept in Treating Patients With Metastatic or Unresectable Kidney Cancer#872532ClinicalTrials.gov
• Tocilizumab, Ipilimumab, and Nivolumab for the Treatment of Advanced Melanoma, Non-Small Cell Lung Cancer, or Urothelial Carcinoma#184850ClinicalTrials.gov
• Combination Chemotherapy Following Surgery in Treating Patients With Advanced Bladder Cancer#908267ClinicalTrials.gov
• Analyzing Clinical Outcomes and Genomic Data of American Indian Patient Population#373587ClinicalTrials.gov
• Vοie ΗΙΡΡΟ et cancer du rein à cellules claires : recherche de nοuveaux biomarqueurs : ΗΙCARE#685098HAL (France)
• Study of PULSAR-ICI +/- IMSA101 in Patients With Oligometastatic NSCLC and RCC#1008538ClinicalTrials.gov
• Fruquintinib Plus Everolimus as 2nd Line Therapy of ccRCC Patients Progressed Post IO and TKI Therapy#1045475ClinicalTrials.gov
• Head-to-head Comparison of Positron Nuclide Radio-labeled FAPI and 18F-FDG PET/CT in Patients With Malignant Tumors#993053ClinicalTrials.gov
• A Beta-only IL-2 ImmunoTherapY Study#245502ClinicalTrials.gov
• Part 2 of Phase 1 Study of GC1008 to Treat Advanced Melanoma (Part 2 Will Only Accept and Treat Patients With Advanced Malignant Melanoma)#866047ClinicalTrials.gov
• Substudy 03C: A Study of Combination Therapies in Participants With Renal Cell Carcinoma With Recurrent Disease During or After Anti-PD-(L)1 Therapy (MK-3475-03C/KEYMAKER-U03)#993468ClinicalTrials.gov
• Pretreatment 18F-FDG PET/CT Radiomics for Predicting Response to First-Line Targeted Therapy Plus Immunotherapy in Metastatic Renal Cell Carcinoma#1046204ClinicalTrials.gov
• Differences in oncological and toxicity outcomes between programmed cell death-1 and programmed cell death ligand-1 inhibitors in metastatic renal cell carcinoma: A systematic review and meta-analysis#391871HAL (France)
• A Study of PDR001 in Combination With LCL161, Everolimus or Panobinostat#918229ClinicalTrials.gov
• Safety Study of Specific Tumor Target Drug Plus Immune System Therapy in Patients With Kidney Cancer#287524ClinicalTrials.gov
• Study Testing the Biologic Activity and Safety of an Immunotherapeutic in Patients With Newly Diagnosed Stage IV Kidney Cancer#303730ClinicalTrials.gov
• A Study of Nivolumab Combined With Ipilimumab Versus Nivolumab Alone in Participants With Advanced Kidney Cancer#979697ClinicalTrials.gov
• International Multicentric Study ARON-1#1045424ClinicalTrials.gov
• PET Quantitative Assessments of Solid Tumor Response to Immune Checkpoint Blockade Therapy#356479ClinicalTrials.gov
• Pilot Study of Intermittent Fasting With Immune Checkpoint Inhibitors#881858ClinicalTrials.gov
• Comparison of In-Home Versus In-Clinic Administration of Subcutaneous Nivolumab Through Cancer CARE (Connected Access and Remote Expertise) Beyond Walls (CCBW) Program#802496ClinicalTrials.gov
• Sorafenib in Treating Patients With Advanced or Metastatic Cancer of the Urinary Tract#826267ClinicalTrials.gov
• Study of NGM831 as Monotherapy and in Combination With Pembrolizumab or Pembrolizumab and NGM438 in Advanced or Metastatic Solid Tumors#824951ClinicalTrials.gov
• A Study to Describe the Kidney Cancer Patient Population Treatment, and Results in the Hospital District of Southwest Finland.#905207ClinicalTrials.gov
• A Study to Learn About How Different Amounts of the Study Medicine PF-07826390 Act in the Body of People With Cancer When Taken Alone or With Other Anti-cancer Medicines.#828040ClinicalTrials.gov